Major trial to determine best drug for rare autoimmune disease
NCT ID NCT07010302
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares five FDA-approved drugs—rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab—to see which best prevents relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that can cause vision loss and paralysis. About 160 adults who test positive for a specific antibody will be randomly assigned to one of the drugs and followed for up to four years. The goal is to find the most effective and safest treatment to help patients and doctors make informed choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab, ravulizumab, inebilizumab, satralizumab, eculizumab
- What this could lead to
- If this trial succeeds, it could identify which of these five drugs best prevents relapses and has fewer side effects, helping patients and doctors choose the most effective treatment for NMOSD.
- What could go wrong
- This is a comparative effectiveness trial, not a test of new drugs. All medications are already approved, so the main uncertainty is which works best in real-world use. Results may not apply to all patients, and side effects are possible with each drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- New hope for NMOSD patients: drug aims to slash relapse rate
- Immune reset: CAR-T therapy targets lupus, MS, and more
- New registry to monitor Real-World effects of NMOSD treatments
- Hormone clues sought in rare nerve disease
- New hope for rare autoimmune disease: eculizumab trial targets relapses